OBJECTIVES:  The aim of this study was to systematically review and sum up data on EQ-5D based health state utilities (HSUs) in patients with all types of lymphomas (ICD-10: C81-C88). This research is a part of review involved EQ-5D in hematologic malignancies, which we performed in February 2016. METHODS:  We ran a systematic search in MEDLINE (PubMed), EMBASE, Cochrane Library, EuroQol website, CEA Registry, LILACS (VHL), ProQuest, CRD and Web of Science. Additional references were obtained from reviewed articles. No study design restrictions were implemented. The search strategy combined MESH, EMTREE and free-text terms respecting the population (Hodgkin lymphoma (HL), follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) in general) and the EQ-5D instruments (EQ-5D-3L, EQ-5D-5L or EQ-5D-Y). Data from studies meeting the inclusion criteria were extracted using a pre-determined extraction form. RESULTS:  In total, 22 full text papers were included into the review, reporting data from 12 clinical trials. We identified 3 (n=189), 3 (n=165) and 6 (n=1031) papers on HL, FL and NHL patients in general (ICD-10: C82-88), respectively. Ten papers from 5 clinical trials (n=816) reported data related to mixed hematologic population (lymphomas and leukemias combined). Health state utility values were reported in ranges: 0.73-0.92; 0.37-0.81; 0.42-0.98, respectively for HL, NHL and mixed hematologic population. In follicular lymphoma one clinical trial was identified, in which progression free survival (PFS) and progressive disease (PD) states utility were reported (0.805; 0.618 respectively, n=165). CONCLUSIONS:  A number of studies reported data on EQ-5D use in patients with lymphomas, although a huge variations in scores were identified. The clinical trials differ in terms of patient characteristics and disease stage, which does not allow to estimate the pooled means.